Keryx Biopharmaceuticals (KERX) CEO Buys 71K Shares After Massive Sell-Off
Tweet
Share
E-mail
Get Alerts KERX Hot Sheet
Join SI Premium – FREE
Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) CEO is trying to instill some confidence in the stock after this week's major sell-off. CEO Ron Bentsur disclosed the purchase of 71,400 shares on 4/4 at $1.3799.
Shares of KERX are down nearly 70% after KRX-0401 + Xeloda did not meet its primary endpoint in a Phase 3 study.
Shares of KERX are down nearly 70% after KRX-0401 + Xeloda did not meet its primary endpoint in a Phase 3 study.
Create E-mail Alert Related Categories
Insider TradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
